• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Appl Thromb Hemost . Thrombin-Antithrombin Complexes and sICAM-1 Are Associated With In-Hospital Mortality in COVID-19 Patients With Inflammatory

tetano

Editor, Senior Moderator
Clin Appl Thromb Hemost

. 2026 Jan-Dec:32:10760296261486177.
doi: 10.1177/10760296261486177. Epub 2026 Sep 1.

Thrombin-Antithrombin Complexes and sICAM-1 Are Associated With In-Hospital Mortality in COVID-19 Patients With Inflammatory Storm​


Michalina Zygmunt 1 , Marcin Kunecki 2 , Leszek Drabik 1 3 4 , Urszula Gancarczyk 1 , Wojciech Płazak 1 3

Affiliations

Free article

Abstract​


AimTo evaluate whether endothelial activation (soluble intercellular adhesion molecule-1, sICAM-1) and thrombotic activation (thrombin-antithrombin complexes, TAT) markers provide prognostic information beyond standard inflammatory markers for in-hospital mortality in COVID-19 patients with cytokine storm.Materials and methodsProspective cohort study of 47 patients with severe SARS-CoV-2 pneumonia admitted November 2020-February 2021 to District Hospital, Debica, Poland. Patients were stratified by cytokine storm profile (CRP >50 mg/L or IL-6 >30 pg/mL) and survival status. Blood biomarkers included CRP, IL-6, sICAM-1, TAT, d-dimer, and antiphospholipid antibodies.ResultsMortality rate was 40.4% (19/47 patients). Among patients with cytokine storm, TAT and sICAM-1 levels were significantly higher in non-survivors versus survivors (TAT: 15.4 (12.2-23.6) ng/mL vs. 11.6 (11.0-14.8) ng/mL, p=0.037; sICAM-1: 12.0 (5.6-35.3) ng/mL vs. 4.3 (2.5-23.9) ng/ml, p=0.033), whereas d-dimer and anticardiolipin IgM did not differentiate mortality outcomes. Elevated TAT was detected in 100% of patients, d-dimer in 93.6%, anticardiolipin IgM in 40.4%, and sICAM-1 in 21.3%. In the multivariable exploratory model based on Firth's logistic regression, TAT ≥12.14 ng/mL and sICAM-1 ≥4.0 ng/mL emerged as potential independent predictors of mortality (OR: 6.27, 95% CI: 1.31-29.99 and OR: 8.68, 95% CI: 1.22-62.15, respectively). Traditional prognostic factors (diabetes on insulin, and blood desaturation) also discriminated poor outcomes.ConclusionssICAM-1 and TAT were associated with in-hospital mortality within the high-risk subgroup of COVID-19 patients with cytokine storm, suggesting prognostic information beyond conventional inflammatory markers and d-dimer. Given the limited sample size, these exploratory findings should be regarded as hypothesis-generating and require validation in larger, multicentre cohorts before informing risk stratification.

Keywords: SARS-CoV-2; endothelial activation/dysfunction; sICAM-1; thrombin-antithrombin complexes (TAT); thrombosis.
 
Back
Top Bottom